<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/uk-health-security-agency">
      <span class="gem-c-organisation-logo__name">UK Health<br>Security<br>Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Desktop Validation Report for Q-POC 
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 18 February 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav aria-label="Contents" class="gem-c-contents-list" data-module="gem-track-click" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 1" data-track-category="contentsClicked" data-track-label="#assay-description-and-intended-purpose-from-the-ifu" data-track-options="{&quot;dimension29&quot;:&quot;\n1.  Assay description and intended purpose (from the IFU)&quot;}" href="#assay-description-and-intended-purpose-from-the-ifu"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Assay description and intended purpose (from the IFU)</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 2" data-track-category="contentsClicked" data-track-label="#type-of-sample-to-be-used-in-validation" data-track-options="{&quot;dimension29&quot;:&quot;\n2.  Type of sample to be used in validation&quot;}" href="#type-of-sample-to-be-used-in-validation"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">Type of sample to be used in validation</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#equipment-and-reagents" data-track-options="{&quot;dimension29&quot;:&quot;\n3.  Equipment and reagents&quot;}" href="#equipment-and-reagents"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Equipment and reagents</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 4" data-track-category="contentsClicked" data-track-label="#performance-characteristics" data-track-options="{&quot;dimension29&quot;:&quot;\n4. \tPerformance characteristics&quot;}" href="#performance-characteristics"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">Performance characteristics</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-category="contentsClicked" data-track-label="#precision-and-robustness" data-track-options="{&quot;dimension29&quot;:&quot;\n5. \tPrecision and robustness&quot;}" href="#precision-and-robustness"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Precision and robustness</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 6" data-track-category="contentsClicked" data-track-label="#analytical-specificity-interferences-and-cross-reactions" data-track-options="{&quot;dimension29&quot;:&quot;\n6. \tAnalytical specificity (Interferences and cross-reactions)&quot;}" href="#analytical-specificity-interferences-and-cross-reactions"><span class="gem-c-contents-list__number">6. </span><span class="gem-c-contents-list__numbered-text">Analytical specificity (Interferences and cross-reactions)</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 7" data-track-category="contentsClicked" data-track-label="#diagnostic-sensitivity-and-specificity" data-track-options="{&quot;dimension29&quot;:&quot;\n7. \tDiagnostic sensitivity and specificity&quot;}" href="#diagnostic-sensitivity-and-specificity"><span class="gem-c-contents-list__number">7. </span><span class="gem-c-contents-list__numbered-text">Diagnostic sensitivity and specificity</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 8" data-track-category="contentsClicked" data-track-label="#summary" data-track-options="{&quot;dimension29&quot;:&quot;\n8.  Summary&quot;}" href="#summary"><span class="gem-c-contents-list__number">8. </span><span class="gem-c-contents-list__numbered-text">Summary</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 9" data-track-category="contentsClicked" data-track-label="#extra-data-tables" data-track-options="{&quot;dimension29&quot;:&quot;\n9.  Extra data tables&quot;}" href="#extra-data-tables"><span class="gem-c-contents-list__number">9. </span><span class="gem-c-contents-list__numbered-text">Extra data tables</span></a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/coronavirus-covid-19-serology-and-viral-detection-tests-technical-validation-reports/desktop-validation-report-for-q-poc
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<h2>
<span class="number">1. </span> Assay description and intended purpose (from the IFU)</h2>

<h3>IFU Q2700 June (draft)</h3>

<p>Q-POC™ is a portable and battery-operated molecular diagnostic system which offers sample to answer analysis within 30 minutes (one sample in 30 minutes per machine).</p>

<p>The SARS-CoV-2 assay is intended for the qualitative detection of nucleic acid from the SARS-CoV-2 viral <abbr title="ribonucleic acid">RNA</abbr> in nasopharyngeal swabs from individuals who are suspected of coronavirus (COVID-19) by their healthcare provider.</p>

<p>Of the MSwab UTM sample, 400ul is loaded onto the disposable microfluidic cassette using a fixed volume pipette (provided) and the cap attached. This creates a fully enclosed device, with no air venting, preventing the generation of amplicon contamination. The disposable is put into the Q-POC™, the patient details added, and test started. The device automatically performs the assay.</p>

<p>Sample prep: Rapid lysis is performed via a heat conditioning step on the cassette. The lysate rehydrates lyophilized <abbr title="polymerase chain reaction">PCR</abbr> reagents, and 3 loci of the SARS-CoV-2 genome are amplified by RT-<abbr title="polymerase chain reaction">PCR</abbr> using a shuttle-flow <abbr title="polymerase chain reaction">PCR</abbr> method, where the <abbr title="polymerase chain reaction">PCR</abbr> reaction mix is oscillated between static heat blocks at 2 distinct temperatures. Microfluidics cycle the sample over these heat blocks, for rapid ramping.</p>

<p>Assay detects Orf1, N, S and human gene RnaseP. DNA detection: Sensitive in-line optics observe the generation of fluorescence as the target region is amplified providing a qPCR read-out, for sample to qPCR result.</p>

<h3>
<span class="number">1.1 </span> Results are for the identification of SARS-CoV-2 <abbr title="ribonucleic acid">RNA</abbr>
</h3>

<p>Positive results are indicative of the presence of SARS-CoV-2 <abbr title="ribonucleic acid">RNA</abbr>; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.</p>

<p>Negative results should be treated as presumptive and, if inconsistent with clinical signs and symptoms or necessary for patient management, should be tested with different authorised or cleared molecular tests. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions.</p>

<p>Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.</p>

<p>This test is intended for use by medical professionals or trained operators who are proficient in performing tests using the Q-POC™ instrument.</p>

<h3>
<span class="number">1.2 </span>	The assay is a standalone test for use on the Q-POC™ instrument</h3>

<h3>
<span class="number">1.3 </span>	There is no viral inactivation report for this assay, and the manufacture makes no claim for viral inactivation</h3>

<p>Due to the initial pipetting step loading the Q-POC™ test cassette should be performed in a biological safety cabinet (BSL II).</p>

<h2>
<span class="number">2. </span> Type of sample to be used in validation</h2>

<p>Copan Nasopharyngeal swabs in Copan MSwab were prospectively collected for dual testing via Q-POC™ SARS-CoV-2 assay and the comparator qPCR assay.</p>

<p>Inclusion criteria:</p>

<ul>
  <li>participants who are suspected of having COVID-19</li>
  <li>nasopharyngeal swab sample collection</li>
</ul>

<p>TVG followed the IFU for samples collection: Copan Nasopharyngeal swab is the validated swab for use. To collect a nasopharyngeal swab sample, carefully insert the swab into the nostril exhibiting the most visible drainage, or the nostril that is most congested if drainage is not visible. Pass the swab directly backwards without tipping the swab head up or down.</p>

<p>The nasal passage runs parallel to the floor, not parallel to the bridge of the nose. Using gentle rotation, insert the swab into the anterior nare parallel to the palate advancing the swab into the nasopharynx, leave in place for a few seconds, and then slowly rotate the swab as it is being withdrawn.</p>

<p>To ensure proper collection, the swab should be passed a distance that is halfway of that from the nose to the tip of the ear. This is about half the length of the swab.</p>

<p>Do not use force while inserting the swab.</p>

<p>The swab should travel smoothly with minimal resistance; if resistance is encountered, withdraw the swab a little bit without taking it out of the nostril. Then elevate the back of the swab and move it forward into the nasopharynx.</p>

<h2>
<span class="number">3. </span> Equipment and reagents</h2>

<h3>
<span class="number">3.1 </span> List all the equipment required that is or is not supplied by the manufacturer</h3>

<p>Product components supplied:</p>

<ul>
  <li>Q-POC™ cartridges (require storage at room temperature)</li>
  <li>fixed pipette for delivery of 400μL; provided with the QuantuMDx Q-POC™ Starter</li>
  <li>Copan MSwab® medium + flexible FLOQswab (catalogue number – 6E013N)</li>
  <li>package insert</li>
  <li>quick reference instructions</li>
</ul>

<p>Product components required but not supplied:</p>

<ul>
  <li>biological safety cabinet (BSL II)</li>
  <li>QuantuMDx Q-POC™ instrument</li>
  <li>disposable, powder-free gloves (latex or nitrile)</li>
  <li>biohazard bag for tips and tube disposal</li>
  <li>10% (v/v) freshly made from household bleach solution (0.5% w/v sodium hypochlorite in water)</li>
  <li>70% ethanol (freshly made)</li>
  <li>dedicated laboratory coats</li>
</ul>

<h3>
<span class="number">3.2 </span>	List all the reagents required that is not provided by the manufacturer with shelf-life expiry dates and storage conditions</h3>

<p>Include positive and negative control materials.</p>

<h2>
<span class="number">4. </span>	Performance characteristics</h2>

<h3>
<span class="number">4.1 </span>	Analytical sensitivity and linearity of SARS-CoV-2 targets</h3>

<h4>4.1.1	Dilution series</h4>

<table>
  <thead>
    <tr>
      <th scope="col">Copies/ml</th>
      <th scope="col">Result on Q-POC™ (Q-PLOT)  (for at least 2 replicates)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>100,000</td>
      <td>Positive</td>
    </tr>
    <tr>
      <td>10,000</td>
      <td>Positive</td>
    </tr>
    <tr>
      <td>7,500</td>
      <td>Positive</td>
    </tr>
    <tr>
      <td>5,000</td>
      <td>Positive</td>
    </tr>
    <tr>
      <td>2,500</td>
      <td>Positive</td>
    </tr>
    <tr>
      <td>1,000</td>
      <td>Positive</td>
    </tr>
  </tbody>
</table>

<h4>4.1.2	Linearity and efficiency</h4>

<p>The assay gives a qualitative result, so this section is not applicable.</p>

<h4>4.1.3	Lowest limits of detection (<abbr title="lowest limits of detection">LLOD</abbr>)</h4>

<p>The <abbr title="lowest limits of detection">LLOD</abbr> stated by the company is 1,000 copies/ml; the data in table 1 confirms that the <abbr title="lowest limits of detection">LLOD</abbr> is &lt;1,000copies/ml.</p>

<h2>
<span class="number">5. </span>	Precision and robustness</h2>

<h3>
<span class="number">5.1 </span>	Intra-assay precision</h3>

<p>The assay gives a qualitative result, so this section is not applicable.</p>

<h3>
<span class="number">5.2 </span>	Inter-assay precision</h3>

<p>The assay gives a qualitative result, so this section is not applicable.</p>

<h3>
<span class="number">5.3 </span>	Repeatability</h3>

<p>This was not performed.</p>

<h2>
<span class="number">6. </span>	Analytical specificity (Interferences and cross-reactions)</h2>

<h3>
<span class="number">6.1 </span>	Cross-reactivity to non-target samples or organisms</h3>

<p>A range of samples either direct clinical samples or spiked samples that are known positives for other diseases, both closely related to be tested.</p>

<table>
  <thead>
    <tr>
      <th scope="col">Zeprometrix cross reactivity panel samples</th>
      <th scope="col">Result with Q-POC</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>B. pertussis A639</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>B. parapertussis A747</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Metapneumovirus 8 (Peru6-2003)</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Coronavirus 229E</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Negative Control</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Coronavirus HKU-1</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Rhinovirus Type 1A</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>M. pneumoniae M129</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>C. pneumoniae CWL-029</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Coronavirus OC43</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Coronavirus NL63</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Parainfluenza 3</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Parainfluenza 4</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>RSV A2</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Adenovirus 1</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Adenovirus 3</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Adenovirus 31</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Influenza AH1 A/NewCal/20/99</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Influenza AH3 A/Brisbane/10/07</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Influenza B B/Florida/02/06</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Parainfluenza 1</td>
      <td>Negative</td>
    </tr>
    <tr>
      <td>Parainfluenza 2</td>
      <td>Negative</td>
    </tr>
  </tbody>
</table>

<h2>
<span class="number">7. </span>	Diagnostic sensitivity and specificity</h2>

<p>Clinical validation with confirmed positives and negatives.</p>

<h3>
<span class="number">7.1 </span>	Diagnostic sensitivity</h3>

<h4>Table 4. Comparison with reference method (note prevalence of 26%)</h4>

<table>
  <thead>
    <tr>
      <td></td>
      <td></td>
      <th scope="col">Comparator</th>
      <th scope="col">Comparator</th>
      <td></td>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>Positive</td>
      <td>Negative</td>
      <td>Total</td>
    </tr>
    <tr>
      <td>Q-POC™  (Q-PLOT)</td>
      <td>Positive</td>
      <td>108</td>
      <td>6</td>
      <td>114</td>
    </tr>
    <tr>
      <td>Q-POC™  (Q-PLOT)</td>
      <td>Negative</td>
      <td>27</td>
      <td>384</td>
      <td>411</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Total</td>
      <td>135</td>
      <td>390</td>
      <td>525</td>
    </tr>
  </tbody>
</table>

<p>Sensitivity = 80.0% (95% CI 72.1-86.2%) this meets the acceptable criteria for sensitivity of the MHRA POC TPP.</p>

<p>It should be noted that there were a high proportion of patients with a CT over 30 which may affect the overall sensitivity.</p>

<h4>Table 5. Performance of Q-POC™ (Q-PLOT) at different viral loads, as defined by CT value</h4>

<p>CT values were only available for 133/135 samples tested.</p>

<table>
  <thead>
    <tr>
      <th scope="col">Basingstoke</th>
      <td></td>
      <td></td>
      <td></td>
      <td></td>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><strong>CT</strong></td>
      <td><strong>Comparator assay Viasure</strong></td>
      <td><strong>Positive match on Q-POC</strong></td>
      <td><strong>Sens %</strong></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&lt;25</td>
      <td>39</td>
      <td>39</td>
      <td>100</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>25-30</td>
      <td>22</td>
      <td>20</td>
      <td>90.9</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>30-35</td>
      <td>19</td>
      <td>13</td>
      <td>68.4</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&gt;35</td>
      <td>6</td>
      <td>0</td>
      <td>0</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>undefined</td>
      <td>0</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>
<br><strong>Gibraltar</strong>
</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td><br></td>
    </tr>
    <tr>
      <td><strong>CT</strong></td>
      <td><strong>Comparator assay QuantumDx <abbr title="polymerase chain reaction">PCR</abbr></strong></td>
      <td><strong>Positive match on Q-POC</strong></td>
      <td><strong>Sens %</strong></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&lt;25</td>
      <td>22</td>
      <td>21</td>
      <td>95.5</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>25-30</td>
      <td>6</td>
      <td>5</td>
      <td>83.3</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>30-35</td>
      <td>8</td>
      <td>5</td>
      <td>62.5</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&gt;35</td>
      <td>6</td>
      <td>1</td>
      <td>16.7</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>undefined</td>
      <td>0</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>
<br> <strong>SGUL</strong>
</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td><strong>CT</strong></td>
      <td><strong>Comparator assay Altona</strong></td>
      <td><strong>Positive match on Q-POC</strong></td>
      <td><strong>Sens %</strong></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&lt;25</td>
      <td>3</td>
      <td>3</td>
      <td>100</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>25-30</td>
      <td>0</td>
      <td>0</td>
      <td>na</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>30-35</td>
      <td>2</td>
      <td>0</td>
      <td>0</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&gt;35</td>
      <td>0</td>
      <td>0</td>
      <td>na</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>undefined</td>
      <td>0</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>
<br><strong>Total</strong>
</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td><strong>CT</strong></td>
      <td><strong>Comparator assay</strong></td>
      <td><strong>Positive match on Q-POC</strong></td>
      <td><strong>Sens %</strong></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&lt;25</td>
      <td>64</td>
      <td>63</td>
      <td>98.4</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>25-30</td>
      <td>28</td>
      <td>25</td>
      <td>89.3</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>30-35</td>
      <td>29</td>
      <td>18</td>
      <td>62.1</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&gt;35</td>
      <td>12</td>
      <td>1</td>
      <td>8.3</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>undefined</td>
      <td>0</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
      <td>&nbsp;</td>
    </tr>
  </tbody>
</table>

<h3>
<span class="number">7.2 </span> 	Diagnostic specificity</h3>

<p>Specificity = 98.5% (95% CI 96.5-99.4%), meets the acceptable criteria for specificity of the MHRA POC TPP.</p>

<h2>
<span class="number">8. </span> Summary</h2>

<p>TVG uses a wide range of sites in order to validate new technologies and tests. These independent sites use a range of RT-qPCR assays against different genomic regions, and it is recognised that for some assay comparisons the sensitivity of RT-qPCR assay(s) may subtly differ from the true sensitivity of the test if compared to the same genomic region.</p>

<p>This assay does meet the acceptable criteria for sensitivity, and the desirable criteria for specificity of the MHRA TPP for POC assays.</p>

<p>The assay has good performance for low CT (&lt;25, high viral load).</p>

<h2>
<span class="number">9. </span> Extra data tables</h2>

<h4>Table 6. Failure rate of the Q-POC assay</h4>

<table>
  <thead>
    <tr>
      <th scope="col">Total number of samples tested</th>
      <th scope="col">Number of IC* failures</th>
      <th scope="col">Percentage of IC failures (%)</th>
      <th scope="col">Number of technical failures</th>
      <th scope="col">Percentage of technical failures (%)</th>
      <th scope="col">Total number of failures</th>
      <th scope="col">Percentage of total failures (%)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>595</td>
      <td>22</td>
      <td>3.7%</td>
      <td>29</td>
      <td>4.9%</td>
      <td>51</td>
      <td>8.6%</td>
    </tr>
  </tbody>
</table>

<p>*internal process control</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>